Vulnerable Patients with Aortic Stenosis: A 5-Year Perspective from PARTNER

Transcatheter valve replacement continues to provide a survival benefit to inoperable patients and seems comparable to surgery in high-risk patients.

Transcatheter aortic valve replacement (TAVR) has emerged as a therapeutic alternative for patients with severe aortic stenosis whose surgical risk is very high or prohibitively high, in part due to findings of the PARTNER trials (inoperable patients: NEJM JW Cardiology May 2012 and N Engl J Med 2012; 366:1696; high-risk patients: NEJM JW Cardiology May 2012 and N Engl J Med 2012; 366:1686). Two manufacturer-sponsored analyses from PARTNER provide insights into the long-term survival patterns of such patients.

Kapadia and colleagues focused on 358 patients with severe aortic stenosis (mean age, 83; mean Society of Thoracic Surgeons estimated risk of 30-day mortality after operative AVR [STS], 11.7%; women, 54%) who were deemed inoperable bec…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)